Skip to main content
. 2022 Jul 7;140(1):16–24. doi: 10.1182/blood.2022015728

Table 2.

Baseline patient characteristics

Characteristic All patients, n = 340
Age, median (range), y 23.5 (1-78)
Sex, n (%)
 Male 197 (57.9)
 Female 143 (42.1)
Primary diagnosis, n (%)
 Hematologic malignancy 188 (55.3)
 Solid malignancy 150 (44.1)
 Nonmalignant conditions 2 (0.6)
Hematologic malignancies, n (%)
 ALL 46 (24.5)
 AML 11 (5.9)
 CLL 11 (5.9)
 CML 8 (4.3)
 NHL 41 (21.8)
 HL 54 (28.7)
 MM 7 (3.7)
 Others 10 (5.3)
Solid tumors, n (%)
 Neuroblastoma 33 (22.0)
 Glioblastoma 19 (12.7)
 Lung cancer 10 (6.7)
 Osteosarcoma 52 (34.7)
 Head and neck 16 (10.7)
 Liver tumors 8 (5.3)
 Others 12 (8.0)
Transplant, n (%)
 Autologous 99 (29.1)
 Allogeneic 83 (24.4)
 No transplant 158 (46.5)
History of radiation therapy, n = 339 (%)
 No 137 (40.4)
 Yes 202 (59.6)
 Median follow-up (range), mo 14.9 (<1-183)
 Cumulative follow-up, y 1027

ALL, acute lymphocytic leukemia; AML, acute myelocytic leukemia; CML, chronic myelocytic leukemia; MM, multiple myeloma; TBI, total body irradiation.